Overview

The marketing authorisation for Zinbryta has been withdrawn at the request of the marketing authorisation holder.

български (BG) (623.68 KB - PDF)

View

español (ES) (541.35 KB - PDF)

View

čeština (CS) (551.54 KB - PDF)

View

dansk (DA) (510.69 KB - PDF)

View

Deutsch (DE) (543.23 KB - PDF)

View

eesti keel (ET) (536.52 KB - PDF)

View

ελληνικά (EL) (628.44 KB - PDF)

View

français (FR) (542.84 KB - PDF)

View

hrvatski (HR) (559.5 KB - PDF)

View

italiano (IT) (536.25 KB - PDF)

View

latviešu valoda (LV) (588.49 KB - PDF)

View

lietuvių kalba (LT) (563.73 KB - PDF)

View

magyar (HU) (598.14 KB - PDF)

View

Malti (MT) (591.98 KB - PDF)

View

Nederlands (NL) (541.57 KB - PDF)

View

polski (PL) (606.49 KB - PDF)

View

português (PT) (541.48 KB - PDF)

View

română (RO) (565.84 KB - PDF)

View

slovenčina (SK) (588.64 KB - PDF)

View

slovenščina (SL) (582.09 KB - PDF)

View

Suomi (FI) (536.58 KB - PDF)

View

svenska (SV) (537.64 KB - PDF)

View

Product information

български (BG) (2.25 MB - PDF)

View

español (ES) (1.32 MB - PDF)

View

čeština (CS) (2.16 MB - PDF)

View

dansk (DA) (1.31 MB - PDF)

View

Deutsch (DE) (1.41 MB - PDF)

View

eesti keel (ET) (1.23 MB - PDF)

View

ελληνικά (EL) (2.63 MB - PDF)

View

français (FR) (1.33 MB - PDF)

View

hrvatski (HR) (2.81 MB - PDF)

View

íslenska (IS) (1.08 MB - PDF)

View

italiano (IT) (1.09 MB - PDF)

View

latviešu valoda (LV) (1.88 MB - PDF)

View

lietuvių kalba (LT) (1.16 MB - PDF)

View

magyar (HU) (1.88 MB - PDF)

View

Malti (MT) (1.91 MB - PDF)

View

Nederlands (NL) (1.07 MB - PDF)

View

norsk (NO) (1.11 MB - PDF)

View

polski (PL) (1.87 MB - PDF)

View

português (PT) (1.09 MB - PDF)

View

română (RO) (1.22 MB - PDF)

View

slovenčina (SK) (1.86 MB - PDF)

View

slovenščina (SL) (1.88 MB - PDF)

View

Suomi (FI) (1.33 MB - PDF)

View

svenska (SV) (1.08 MB - PDF)

View

Latest procedure affecting product information: IB/0015

27/03/2018

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (517.25 KB - PDF)

View

español (ES) (481.09 KB - PDF)

View

čeština (CS) (488.17 KB - PDF)

View

dansk (DA) (459.95 KB - PDF)

View

Deutsch (DE) (479.68 KB - PDF)

View

eesti keel (ET) (483.13 KB - PDF)

View

ελληνικά (EL) (518.75 KB - PDF)

View

français (FR) (493.52 KB - PDF)

View

hrvatski (HR) (488.31 KB - PDF)

View

íslenska (IS) (481.38 KB - PDF)

View

italiano (IT) (481.24 KB - PDF)

View

latviešu valoda (LV) (511.88 KB - PDF)

View

lietuvių kalba (LT) (498.05 KB - PDF)

View

magyar (HU) (510.29 KB - PDF)

View

Malti (MT) (511.19 KB - PDF)

View

Nederlands (NL) (480.33 KB - PDF)

View

norsk (NO) (487.39 KB - PDF)

View

polski (PL) (525.13 KB - PDF)

View

português (PT) (480.86 KB - PDF)

View

română (RO) (498.61 KB - PDF)

View

slovenčina (SK) (508.81 KB - PDF)

View

slovenščina (SL) (37.55 KB - PDF)

View

Suomi (FI) (480.09 KB - PDF)

View

svenska (SV) (17.62 KB - PDF)

View

Product details

Name of medicine
Zinbryta
Active substance
daclizumab
International non-proprietary name (INN) or common name
daclizumab
Therapeutic area (MeSH)
Multiple Sclerosis
Anatomical therapeutic chemical (ATC) code
L04AC01

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).

Authorisation details

EMA product number
EMEA/H/C/003862
Marketing authorisation holder
Biogen Idec Ltd

Innovation House
70 Norden Road
Maidenhead
Berkshire SL6 4AY
United Kingdom

Opinion adopted
31/03/2016
Marketing authorisation issued
01/07/2016
Revision
8

Assessment history

This page was last updated on

How useful do you find this page?